The glycine receptor beta subunit (GLRB) is a key component of inhibitory glycine receptors (GlyRs), which are ligand-gated chloride channels mediating synaptic inhibition in the central nervous system. GlyRs are pentameric complexes typically composed of alpha (α1-α4) and beta (β) subunits, with GLRB forming the structural backbone that anchors receptors to the postsynaptic membrane. GLRB antibodies are immunological tools used to study the expression, localization, and function of GlyRs in neurological tissues. These antibodies have been critical in research on glycinergic neurotransmission, particularly in spinal cord and brainstem circuits regulating motor coordination, pain perception, and respiratory rhythms. Dysfunction of GLRB is linked to hyperekplexia (startle disease), a rare neurological disorder characterized by excessive startle responses and muscle rigidity. Commercially available GLRB antibodies are typically developed in rabbits or mice using synthetic peptides or recombinant proteins corresponding to specific extracellular or intracellular domains. Validation methods include Western blotting, immunohistochemistry, and knockout tissue controls. Recent applications extend to investigating GlyR involvement in neurodevelopmental disorders, chronic pain mechanisms, and neurodegenerative conditions. Proper antibody selection requires attention to species reactivity, epitope specificity, and experimental compatibility.